Literature DB >> 14709620

Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases.

Deepak K Dalvie1, Thomas N O'Connell.   

Abstract

Ticlopidine is an agent that inhibits adenosine diphosphate-induced platelet aggregation. Metabolic studies with ticlopidine have indicated that the principal routes of metabolism are N-dealkylation, N-oxidation, and oxidation of the thiophene ring. However, ticlopidine shares some structural features that are similar to those of cyclic tertiary amines such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and tetrahydroisoquinolines, which are converted to neurotoxic pyridinium metabolites, via the iminium (dihydropyridinium) species. The current in vitro studies examined the potential of ticlopidine to undergo a similar conversion by cytochrome P450 (P450), peroxidases, and monoamine oxidase (MAO). The results from these studies have suggested that ticlopidine undergoes an overall 4-electron oxidation to the novel thienopyridinium metabolite (M6) via the intermediate 2-electron oxidation product, the thienodihydropyridinium metabolite (M5) by P450, horseradish peroxidase, and myeloperoxidase and, to a lesser extent, by MAO. The structures of these metabolites were characterized by liquid chromatography (LC)-tandem mass spectrometry and LC-NMR. Qualitative studies with baculovirus-expressed P450s revealed the involvement of P450 3A4 in this conversion. Interestingly, M5 was the primary metabolite in the peroxidase-mediated reactions and was quite stable to air oxidation or disproportionation. It was less electrophilic and did not form cyanide, glutathione, or N-acetylcysteine adducts. On the other hand, M6 was the major metabolite in P450-catalyzed oxidation of ticlopidine. The results from this study have revealed that in addition to metabolism of the thiophene ring of ticlopidine, the tetrahydropyridine moiety of the compound is susceptible to a 2-electron and a 4-electron oxidation like other cyclic tertiary amines.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14709620     DOI: 10.1124/dmd.32.1.49

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Formation and Cleavage of C-C Bonds by Enzymatic Oxidation-Reduction Reactions.

Authors:  F Peter Guengerich; Francis K Yoshimoto
Journal:  Chem Rev       Date:  2018-06-22       Impact factor: 60.622

Review 2.  Plasticity of CYP2B enzymes: structural and solution biophysical methods.

Authors:  P Ross Wilderman; James R Halpert
Journal:  Curr Drug Metab       Date:  2012-02       Impact factor: 3.731

3.  Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel .

Authors:  Sean C Gay; Arthur G Roberts; Keiko Maekawa; Jyothi C Talakad; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Biochemistry       Date:  2010-09-15       Impact factor: 3.162

4.  Identification of the Significant Involvement and Mechanistic Role of CYP3A4/5 in Clopidogrel Bioactivation.

Authors:  Yaoqiu Zhu; Jiang Zhou
Journal:  ACS Med Chem Lett       Date:  2012-09-09       Impact factor: 4.345

5.  Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.

Authors:  Jyothi C Talakad; Manish B Shah; Gregory S Walker; Cathie Xiang; James R Halpert; Deepak Dalvie
Journal:  Drug Metab Dispos       Date:  2010-12-14       Impact factor: 3.922

6.  Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back.

Authors:  James R Halpert
Journal:  Drug Metab Dispos       Date:  2011-04-18       Impact factor: 3.922

Review 7.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.